Assessing hepatic impairment with biomarker-informed physiologically based pharmacokinetic modeling: Strengths and limitations of the endogenous biomarker Coproporphyrin I
Drug Metabolism and Disposition · 2026
DOI: 10.1016/j.dmd.2025.100209 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026. Verfasst von Jakub Witkowski und 4 weiteren Autor:innen. Beteiligte Einrichtung: Certara UK Ltd., Certara Predictive Technologies, Sheffield, United Kingdom. Electronic address: jakub.witkowski@certara.com. Hauptthemen laut MEDLINE: Coproporphyrins, Models, Biological, Liver, Liver Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 93 Literaturangaben.
Abstract (Originalsprache)
Plasma levels of Coproporphyrin I (CP-I), an endogenous biomarker used to gauge hepatic organic anion transporting polypeptide (OATP)1B1 and OATP1B3 activities, are linked to covariates, namely ethnicity, sex, and hemoglobin level. We developed and verified a mechanistic physiologically based pharmacokinetic model for CP-I considering these covariates in basal conditions and with a range of OATP1B perpetrators in virtual healthy subjects of various ethnicities. Simulations recovered the observed steady-state baseline levels and concentrations with interaction (Cmax and area under the curve ratios, n = 12 studies) within 2-fold. Published CP-I plasma data in hepatic impairment (HI) indicated a progressive reduction in OATP1B activity in vivo. We applied our verified CP-I model to simulate CP-I plasma levels reported in individuals with increasing severity of HI as classified based on the Child-Pugh classes (A, B, and C) to assess the hepatic OATP1B transporter activity in cirrhotic virtual populations. A biomarker-informed physiologically based pharmacokinetic (BI-PBPK) approach was applied to close the gap between known expression differences for human hepatic OATP1B and multidrug resistance-associated protein 2 (MRP2) in HI and observed activity differences in HI relative to healthy individuals. HI-associated relative activity factor scalars derived from BI-PBPK simulations were developed and verified using 9 OATP1B substrates (n = 7 studies), with an average fold error and absolute average fold error of 0.93 and 1.74 for Cmax, and 1.29 and 1.47 for area under the plasma concentration-time curve ratios between HI and healthy. The BI-PBPK approach offers a powerful means to establish model system parameters to improve predictive performance, particularly in disease populations and to explore the mechanisms behind the changes in plasma level. SIGNIFICANCE STATEMENT: Biomarker-informed physiologically based pharmacokinetic approach was used to bridge abundance differences in transporter expression and observed activity differences between healthy volunteer and hepatically impaired patients. A PBPK model for the endogenous biomarker, Coproporphyrin I, was developed where its synthesis rate is linked to body weight, sex, ethnicity, and hemoglobin levels. The model was verified with an extensive set of weak-to-strong OATP1B perpetrator drugs and applied to recover plasma concentrations for multiple OATP1B substrates using associated drug-drug interactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Certara UK Ltd., Certara Predictive Technologies, Sheffield, United Kingdom. Electronic address: jakub.witkowski@certara.com.
- Certara UK Ltd., Certara Predictive Technologies, Sheffield, United Kingdom.
Zitieren
APA
Witkowski, J., Neuhoff, S., De Sousa Mendes, M., Bois, F. Y., & Harwood, M. D. (2026). Assessing hepatic impairment with biomarker-informed physiologically based pharmacokinetic modeling: Strengths and limitations of the endogenous biomarker Coproporphyrin I. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2025.100209
Vancouver
Witkowski J, Neuhoff S, De Sousa Mendes M, Bois FY, Harwood MD. Assessing hepatic impairment with biomarker-informed physiologically based pharmacokinetic modeling: Strengths and limitations of the endogenous biomarker Coproporphyrin I. Drug Metabolism and Disposition. 2026. doi:10.1016/j.dmd.2025.100209
BibTeX
@article{Witkowski2026,
author = {Witkowski, Jakub and Neuhoff, Sibylle and De Sousa Mendes, Mailys and Bois, Frederic Y and Harwood, Matthew D},
title = {Assessing hepatic impairment with biomarker-informed physiologically based pharmacokinetic modeling: Strengths and limitations of the endogenous biomarker Coproporphyrin I},
journal = {Drug Metabolism and Disposition},
year = {2026},
doi = {10.1016/j.dmd.2025.100209}
}
EUVIMED